Identification of novel VHL targets that are associated with the development of renal cell carcinoma

Oncogene

Volumn 26, Issue 11, 2007, Pages 1661-1672

  Abdulrahman, M ^a   Maina, E N ^a   Morris, M R ^a   Zatyka, M ^a   Raval, R R ^b   Banks, R E ^c   Wiesener, M S ^d   Richards, F M ^a   Johnson, C M ^e   Latif, F ^a   Maher, E R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Gene expression; Microarray; Renal cell carcinoma; VHL

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA SMOOTH MUSCLE ACTIN; MUTANT PROTEIN; PROTEINASE ACTIVATED RECEPTOR 2; THYMOSIN;

ARTICLE; CELL GROWTH; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CARCINOMA; MICROARRAY ANALYSIS; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; VON HIPPEL LINDAU DISEASE;

BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE; DNA PRIMERS; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; KIDNEY NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33947162517     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209932     Document Type: Article

References (57)

1. Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K et al. (2003). Loss of von Hippel-Lindau protein causes cell density dependent deregulation of cyclin D1 expression through hypoxia-inducible factor. Oncogene 22: 2728-2738.
2. Bertog M, Letz B, Kong W, Steinhoff M, Higgins MA, Bielfeld-Ackermann A et al. (1999). Basolateral proteinase-activated receptor (PAR-2) induces chloride secretion in M-1 mouse renal cortical collecting duct cells. J Physiol 521(Part 1): 3-17.
3. Bindra RS, Vasseli JR, Stearman R, Linehan WM, Klausner RD. (2002). VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62: 3014-3019.
4. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490.
5. Cha HJ, Jeong MJ, Kleinman HK. (2003). Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 1995: 1674-1680.
6. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH et al. (2001). Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10: 1029-1038.
7. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC et al. (2000). Hypoxia induciblefactor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741.
8. Cocks TM, Sozzi V, Moffatt JD, Selemidis S. (1999). Protease-activated receptors mediate apamin-sensitive relaxation of mouse and guinea pig gastrointestinal smooth muscle. Gastroenterology 116: 586-592.
9. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, et al. (1994). Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 3: 1303-1308.
10. Danahay H, Withey L, Poll CT, van de Graaf SF, Bridges RJ. (2001). Protease-activated receptor-2-mediated inhibition of ion transport in human bronchial epithelial cells. Am J Physiol Cell Physiol 280: C1455-C1464.
11. Dery O, Corvera CU, Steinhoff M, Bunnett NW. (1998). Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 274: C1429-C1452.
12. Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, Hollenberg MD et al. (2001). Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci USA 98: 13936-13941.
13. Frohm M, Gunne H, Bergman AC, Agerberth B, Bergman T, Boman A et al. (1996). Biochemical and antibacterial analysis of human wound and blister fluid. Eur J Biochem 237: 86-92.
14. Frungieri MB, Weidinger S, Meineke V, Kohn FM, Mayerhofer A. (2002). Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma: Possible relevance to human fibrotic disorders. Proc Natl Acad Sci USA 99: 15072-15077.
15. Grant DS, Kinsella JL, Kibbey MC, LaFlamme S, Burbelo PD, Goldstein Al et al. (1995). Matrigel induces thymosin beta 4 gene in differentiating endothelial cells. J Cell Sci 108(Part 12): 3685-3694.
16. Hall AK. (1991). Differential expression of thymosin genes in human tumors and in the developing human kidney. Int J Cancer 48: 672-677.
17. Hall AK. (1994). Molecular interactions between G-actin, DNase I and the beta-thymosins in apoptosis: a hypothesis. Med Hypotheses 43: 125-131.
18. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin Jr WG. (2001). von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10: 1019-1027.
19. Hollenberg MD. (2002). PARs in the stars: proteinase-activated receptors and astrocyte function. Focus on 'thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways'. Am J Physiol Cell Physiol 283: C1347-C1350.
20. Hoogerwerf WA, Zou L, Shenoy M, Sun D, Micci MA, Lee-Hellmich H et al. (2001). The proteinase-activated receptor 2 is involved in nociception. J Neurosci 21: 9036-9042.
21. Huff T, Muller CS, Otto AM, Netzker R, Hannappel E. (2001). beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol 33: 205-220.
22. Iguchi K, Usami Y, Hirano K, Hamatake M, Shibata M, Ishida R. (1999). Decreased thymosin beta4 in apoptosis induced by a variety of antitumor drugs. Biochem Pharmacol 57: 1105-1111.
23. Jiang Y, Zhang W, Kondo K, Klco JM, St Martin TB, Dufault MR et al. (2003). Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 1: 453-462.
24. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. (2000). Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97: 10430-10435.
25. Knauth K, Bex C, Jemth P, Buchberger A. (2006). Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. Oncogene 25: 370-377.
26. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr WG. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246.
27. Kondo K, Kim WY, Lechpammer M, Kaelin Jr WG. (2003). Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PloS Biol 1: E83.
28. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP et al. (2005). Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155-167.
29. Li D, Das S, Yamada T, Samuels HH. (2004). The NRIF3 family of transcriptional coregulators induces rapid and profound apoptosis in breast cancer cells. Mol Cell Biol 24: 3838-3848.
30. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM et al. (2003). von Hippel-Lindau disease. Lancet 361: 2059-2067.
31. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R et al. (1991). Von Hippel-Lindau disease: a genetic study. J Med Genet 28: 443-447.
32. Maher ER. (2004). Von Hippel-Lindau disease. Curr Mol Med 4: 833-842.
33. Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM et al. (2005). Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene 24: 4549-4558.
34. Malinda KM, Goldstein AL, Kleinman HK et al. (1997). Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J 11: 474-481.
35. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. (2002). The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255.
36. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
37. Maxwell PH, Ratcliffe PJ. (2002). Oxygen sensors and angiogenesis. Semin Cell Dev Biol 13: 29-37.
38. Maxwell PH. (2005). The HIF pathway in cancer. Semin Cell Dev Biol 16: 523-530.
39. Milia AF, Salis MB, Stacca T, Pinna A, Madeddu P, Trevisani M. (2002). Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. Circ Res 91: 346-352.
40. Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE. (2005). Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res 165: 4598-4606.
41. Neumann HPH, Eng C, Mulligan L, Glavac D, Ponder BAJ, Crossey PA et al. (1995). Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 274: 1149-1151.
42. Nguyen TD, Moody MW, Steinhoff M, Okolo C, Koh DS, Bunnett NW. (1999). Trypsin activates pancreatic duct epithelial cell ion channels through proteinase-activated receptor-2. J Clin Invest 103: 261-269.
43. Niu M, Nachmias VT. (2000). Increased resistance to apoptosis in cells overexpressing thymosin beta four: a role for focal adhesion kinase pp125FAK. Cell Adhes Commun 7: 311-320.
44. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE et al. (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427.
45. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL et al. (2005). Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686.
46. Richard DE, Vouret-Craviari V, Pouyssegur J. (2001). Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene 20: 1556-1562.
47. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. (2003). Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425: 307-311.
48. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. (2001). Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 22: 146-152.
49. Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. (2005). Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293 T cells. Cancer Res 65: 3299-3306.
50. Webster AR, Richards FM, MacRonald FE, Moore AT, Maher ER. (1998). An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet 63: 1025-1035.
51. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A et al. (2001). Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 61: 5215-5222.
52. Woodward ER, Eng C, McMahon R, Voutilainen R, Affara NA, Ponder BAJ et al. (1997). Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet 6: 1051-1056.
53. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. (2000). Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19: 6297-6305.
54. Wykoff CC, Sotiriou C, Cockman ME, Ratcliffe PJ, Maxwell P, Liu E et al. (2004). Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 90: 1235-1243.
55. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434.
56. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU et al. (2002). Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62: 3803-3811.
57. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM et al. (1996). Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8: 348-357.